2,N-dimethyl-benzene-1,3-diamine | 848480-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,N-dimethyl-benzene-1,3-diamine
• 英文别名: N1,2-dimethylbenzene-1,3-diamine；3-N,2-dimethylbenzene-1,3-diamine
• CAS: 848480-16-0
• 化学式: C₈H₁₂N₂
• mdl: MFCD17284916
• 分子量: 136.197
• InChiKey: IBCHQTPSKZPOQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N,2-dimethyl-3-nitroaniline 在 palladium 10% on activated carbon sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 2,N-dimethyl-benzene-1,3-diamine
  参考文献：
  名称：

  [EN] 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS
  [FR] DERIVES DE 2,4-DI(HETERO)-ARYLAMINO-PYRIMIDINE COMME INHIBITEURS DES KINASES ZAP-70 ET/OU SYK

  摘要：

  公开了具有以下式（I）的嘧啶衍生物；其中R0、R1、R3至R9和Z具有如权利要求1所示的含义，具有ZAP-70和/或Syk抑制活性。

  公开号：

  WO2005026158A1

文献信息

• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• [EN] BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ALCYNES BICYCLIQUES ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015050505A1

  公开（公告）日：2015-04-09

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases

  本发明涉及某些化合物（例如，咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物预防和治疗疾病（例如，增殖性疾病（例如癌症）、炎症性疾病、自身免疫性疾病、代谢性疾病和神经退行性疾病（例如自闭症、自闭症谱系障碍、阿尔茨海默病））的用途，以及治疗这些疾病的方法。
• 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors
  申请人：Baenteli Rolf

  公开号：US20060247262A1

  公开（公告）日：2006-11-02

  Disclosed are pyrimidine derivatives of formula wherein R 0 , R 1 , R 3 to R 9 , and Z have a signification as indicated in claim 1, which have interesting pharmaceutical properties.

  本发明揭示了一种嘧啶衍生物，其化学式为其中R0，R1，R3至R9和Z的含义如权利要求1所示，具有有趣的药物特性。
• 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors
  申请人：Baenteli Rolf

  公开号：US20100152182A1

  公开（公告）日：2010-06-17

  Disclosed are pyrimidine derivatives of formula wherein R 0 , R 1 , R 3 to R 9 , and Z have a signification as indicated in claim 1 , which have interesting pharmaceutical properties.

  本发明涉及一种嘧啶衍生物，其化学式如下：其中，R0、R1、R3至R9和Z的含义如权利要求1所示，具有有趣的药理特性。
• BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20160229860A1

  公开（公告）日：2016-08-11

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），它们作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的制药组合物，并用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、自身免疫性疾病、代谢性疾病和神经退行性疾病（例如自闭症、自闭症谱系障碍、阿尔茨海默病）），以及治疗这些疾病的方法。